Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients

Cancer Immunology, Immunotherapy

Volumn 64, Issue 11, 2015, Pages 1475-1485

  Yan, Fan ^a,b   Du, Ruijuan ^a,b   Wei, Feng ^a,b   Zhao, Hua ^a,b   Yu, Jinpu ^a,b   Wang, Changli ^a,b   Zhan, Zhongli ^a,b   Ding, Tingting ^a,b   Ren, Xiubao ^a,b   Chen, Xin ^c   Li, Hui ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c UNIVERSITY OF MACAU   (Macao)

Author keywords

CD4+FoxP3+ regulatory T cells; Clinical pathology; Immunosuppression; Lung cancer; Tumor necrosis factor receptor type II (TNFR2)

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; ENZYME REPRESSION; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CARCINOGENESIS; LYMPH VESSEL METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; PATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; T CELL CULTURE; TUMOR INVASION; TURNOVER TIME; UPREGULATION; AGED; BIOSYNTHESIS; IMMUNOLOGY; IMMUNOPHENOTYPING; LUNG TUMOR; PHYSIOLOGY;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY;

EID: 84945476102     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1751-z     Document Type: Article

References (42)

1. − T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67(1–2):1–12. doi:10.1016/j.humimm.2005.11.005
2. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H (2012) Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 75(1):95–101. doi:10.1016/j.lungcan.2011.06.002
3. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163(10):5211–5218
4. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194(6):823–832
5. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9(2):606–612
6. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D (2012) Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77(2):306–311. doi:10.1016/j.lungcan.2012.04.011
7. Hasegawa T, Suzuki H, Yamaura T, Muto S, Okabe N, Osugi J, Hoshino M, Higuchi M, Ise K, Gotoh M (2014) Prognostic value of peripheral and local forkhead box P3 regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol 2(5):685–694. doi:10.3892/mco.2014.299
8. +FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 42(7):1876–1885. doi:10.1002/eji.201142347
9. +regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 186(7):4388–4395
10. +Treg-cell function and disease suppression in EAE. Eur J Immunol 42(2):403–412. doi:10.1002/eji.201141659
11. +T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 180(10):6467–6471
12. Ryba M, Rybarczyk-Kapturska K, Zorena K, Myśliwiec M, Myśliwska J (2011) Lower frequency of CD62L(high) and higher frequency of TNFR2(+) Tregs are associated with inflammatory conditions in type 1 diabetic patients. Mediat Inflamm 2011:645643. doi:10.1155/2011/645643
13. Minigo G, Woodberry T, Piera KA, Salwati E, Tjitra E, Kenangalem E, Price RN, Engwerda CR, Anstey NM, Plebanski M (2009) Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog 5(4):e1000402. doi:10.1371/journal.ppat.1000402
14. +Tregs within the tumor microenvironment. Clin Immunol 149(1):97–110. doi:10.1016/j.clim.2013.07.003
15. Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M (2014) Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol 89(8):795–802. doi:10.1002/ajh.23746
16. +regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res 20(3):724–735. doi:10.1158/1078-0432.ccr-13-1576
17. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA (2009) Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 58(8):1219–1228. doi:10.1007/s00262-008-0628-9
18. +regulatory T cells in human peripheral blood. Eur J Immunol 40(4):1099–1106. doi:10.1002/eji.200940022
19. +T reg cells. J Exp Med 203(7):1701–1711. doi:10.1084/jem.20060772
20. Yu N, Li X, Song W, Li D, Yu D, Zeng X, Li M, Leng X (2012) CD4(+)CD25(+)CD127 (low/-) T Cells: a more specific Treg population in human peripheral blood. Inflammation 35(6):1773–1780. doi:10.1007/s10753-012-9496-8
21. Kim EY, Priatel JJ, Teh SJ, Teh HS (2006) TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176(2):1026–1035
22. Kim EY, Teh HS (2004) Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 173(7):4500–4509
23. Soares A, Govender L, Hughes J, Mavakla W, de Kock M, Barnard C, Pienaar B, Janse van Rensburg E, Jacobs G, Khomba G, Stone L, Abel B, Scriba TJ, Hanekom WA (2010) Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods 362(1–2):43–50. doi:10.1016/j.jim.2010.08.007
24. +regulatory T cells. J Immunol 185(1):174–182. doi:10.4049/jimmunol.0903548
25. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25(+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192(2):303–310
26. +T cells in the lymphopenic setting by HSV amplicon transduction. Cancer Immunol Immunother 57(5):663–675. doi:10.1007/s00262-007-0405-1
27. Blankenstein T, Qin Z (2003) The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 15(2):148–154
28. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107–1111. doi:10.1038/35074122
29. Wang WJ, Tao Z, Gu W, Sun LH (2013) Variation of blood T lymphocyte subgroups in patients with non- small cell lung cancer. Asian Pac J Cancer Prev P 14(8):4671–4673
30. De Vita F, Orditura M, Auriemma A, Infusino S, Catalano G (1998) Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res 17(4):413–417
31. Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6(3):103–107
32. Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X (2011) TNF optimally activates regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol 41(7):2010–2020. doi:10.1002/eji.201041205
33. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100(14):8372–8377
34. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5(5):e10436. doi:10.1371/journal.pone.0010436
35. +) T Cells Induced upon TCR Stimulation of CD4 T Cells identifies maximal cytokine-producing effectors. Front Immunol 4:233. doi:10.3389/fimmu.2013.00233
36. Rothe J, Gehr G, Loetscher H, Lesslauer W (1992) Tumor necrosis factor receptors–structure and function. Immunol Res 11(2):81–90
37. +regulatory T. cell phenotype in the inflammatory environment. J Immunol 190(3):1076–1084
38. Housley WJ, Adams CO, Nichols FC, Puddington L, Lingenheld EG, Zhu L, Rajan TV, Clark RB (2011) Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol 186(12):6779–6787. doi:10.4049/jimmunol.1003868
39. Chen X, Willette-Brown J, Wu X, Hu Y, Howard OM, Oppenheim JJ (2015) IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. Faseb J 29(2):443–454
40. Rauert H, Wicovsky A, Muller N, Siegmund D, Spindler V, Waschke J, Kneitz C, Wajant H (2010) Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem 285(10):7394–7404
41. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL (2004) Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 279(31):32869–32881
42. Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M, Ciuffetta A, Colantoni S, Vacca A, Frati L, Gulino A, Felli MP, Screpanti I (2011) Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. J Immunol 186(11):6199–6206